(IPHA), Astrazeneca PLC (NYSE:AZN) – Innate Pharma Rallies On Acceptance Of European Regulatory Application For Leukemia Drug

Shares of small-cap biotech Innate Pharma (NASDAQ: IPHA) are advancing strongly after the oncology-focused French biotech said the European Medicines Agency, or EMA, has accepted the Marketing Authorization Application for Lumoxiti. Lumoxiti is a CD22-directed immunotoxin and a first-in-class medicine, which has been approved in the U.S. for treating adult patients…